LeonaBio (LONA) Gains from Sales and Divestitures (2020 - 2026)
LeonaBio (LONA) reported Gains from Sales and Divestitures of $57601.0 for Q1 2026, up 3740.07% year-over-year from $1500.0 in Q1 2025, and down 2.66% on a QoQ basis from $59177.0 in Q4 2025.
LeonaBio (LONA) has 6 years of Gains from Sales and Divestitures data on file, last reported at $57601.0 in Q1 2026.
- Quarterly Gains from Sales and Divestitures rose 3740.07% year-over-year to $57601.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57601.0 (up 3740.07% YoY) and the FY2025 annual result came in at $59177.0, down 90.47% from the prior year.
- Gains from Sales and Divestitures slipped to $57601.0 in Q1 2026 per LONA's latest filing, from $59177.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $620668.0 in Q4 2024 and bottomed at $1500.0 in Q1 2025.
- The 4-year median for Gains from Sales and Divestitures is $119911.0 (2022), against an average of $170589.4.
- The widest annual swing landed in 2022, when Gains from Sales and Divestitures jumped 7508.57%; it then slumped 99.03% in 2025.
- Tracing LONA's Gains from Sales and Divestitures over 4 years: stood at $119911.0 in 2022, then jumped by 417.61% to $620668.0 in 2024, then tumbled by 90.47% to $59177.0 in 2025, then declined by 2.66% to $57601.0 in 2026.
- Per Business Quant, the three latest LONA Gains from Sales and Divestitures figures stand at $57601.0 (Q1 2026), $59177.0 (Q4 2025), and $29829.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,601.00 |
| Mar 31, 2026 | 57,601.00 |
| Dec 31, 2025 | 59,177.00 |
| Dec 31, 2025 | 59,177.00 |
| Sep 30, 2025 | 29,829.00 |
| Sep 30, 2025 | 29,829.00 |
| Jun 30, 2025 | 298,380.00 |
| Jun 30, 2025 | 298,380.00 |
| Mar 31, 2025 | 1,500.00 |
| Mar 31, 2025 | 1,500.00 |
| Dec 31, 2024 | 620,668.00 |
| Dec 31, 2024 | 620,668.00 |
| Sep 30, 2024 | 310,087.00 |
| Sep 30, 2024 | 310,087.00 |
| Jun 30, 2024 | 156,049.00 |
| Jun 30, 2024 | 156,049.00 |
| Mar 31, 2024 | 154,049.00 |
| Mar 31, 2024 | 154,049.00 |
| Dec 31, 2022 | 119,911.00 |
| Dec 31, 2022 | 119,911.00 |
| Sep 30, 2022 | 119,911.00 |
| Sep 30, 2022 | 119,911.00 |
| Jun 30, 2022 | 119,911.00 |
| Jun 30, 2022 | 119,911.00 |
| Dec 31, 2021 | 4,204.00 |
| Dec 31, 2021 | 4,204.00 |
| Sep 30, 2021 | 4,204.00 |
| Sep 30, 2021 | 4,204.00 |
| Jun 30, 2021 | 1,576.00 |
| Jun 30, 2021 | 1,576.00 |
| Mar 31, 2021 | 1,576.00 |
| Mar 31, 2021 | 1,576.00 |
| Dec 31, 2020 | 4,203.00 |
| Dec 31, 2020 | 4,203.00 |
| Sep 30, 2020 | 4,203.00 |
| Sep 30, 2020 | 4,203.00 |